Changeflow GovPing Pharma & Drug Safety MEDICON Anti-inflammatory, Anti-cancer, and Ant...
Priority review Rule Added Final

MEDICON Anti-inflammatory, Anti-cancer, and Anti-angiogenic Compounds Patent

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO granted patent US12599599B2 to MEDICON PHARMACEUTICALS, INC. covering compounds of general Formula A-D-Y with anti-inflammatory, anti-cancer, and anti-angiogenic activity for treating inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. The patent includes pharmaceutical compositions, methods of making, and methods of use with 4 claims.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO granted patent US12599599B2 to MEDICON PHARMACEUTICALS, INC. covering compounds of Formula A-D-Y with anti-inflammatory, anti-cancer, and anti-angiogenic activity for treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. The patent includes 4 claims on pharmaceutical compositions, methods of making, and methods of use.

For pharmaceutical companies and manufacturers developing therapeutics in these disease areas, this patent establishes exclusionary rights that may affect freedom-to-operate assessments and competitive landscape analysis for anti-inflammatory, anti-cancer, and cardiovascular drug development programs.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof

Grant US12599599B2 Kind: B2 Apr 14, 2026

Assignee

MEDICON PHARMACEUTICALS, INC.

Inventors

Basil Rigas

Abstract

Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.

CPC Classifications

A61P 27/02 A61P 35/00 A61P 27/04 A61P 29/00 C07C 233/78 C07C 323/62 C07C 317/44 C07D 241/04 C07D 295/185 C07F 9/222 C07F 9/2458 C07F 9/650952

Filing Date

2023-07-20

Application No.

18355811

Claims

4

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
US12599599B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent issuance Therapeutic compound development Pharmaceutical manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!